These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16879440)

  • 1. Preliminary evidence that the allogeneic response might trigger antitumour immunity in patients with advanced prostate cancer.
    Muir G; Rajbabu K; Callen C; Fabre JW
    BJU Int; 2006 Nov; 98(5):989-95. PubMed ID: 16879440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer.
    Eaton JD; Perry MJ; Nicholson S; Guckian M; Russell N; Whelan M; Kirby RS
    BJU Int; 2002 Jan; 89(1):19-26. PubMed ID: 11849155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation.
    Uhlin M; Okas M; Karlsson H; Gertow J; Henningsohn L; Ringdén O; Kärre K; Levitsky V; Mattsson J
    Transplantation; 2009 Feb; 87(4):467-72. PubMed ID: 19307781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
    Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
    Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
    Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M
    Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunology and immunotherapy approaches for prostate cancer.
    Elkord E
    Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
    Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
    J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy of hormone-refractory, stage D2 prostate cancer using ex vivo activated autologous T cells (autolymphocyte therapy): results from a pilot study.
    Ross S; Liu V; Abulafia R; Hogan C; Osband M
    Biotechnol Ther; 1993; 4(3-4):197-211. PubMed ID: 7507387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
    Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
    BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer.
    Kennedy-Smith AG; McKenzie JL; Owen MC; Davidson PJ; Vuckovic S; Hart DN
    J Urol; 2002 Aug; 168(2):741-7. PubMed ID: 12131362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.
    Small EJ; Sacks N; Nemunaitis J; Urba WJ; Dula E; Centeno AS; Nelson WG; Ando D; Howard C; Borellini F; Nguyen M; Hege K; Simons JW
    Clin Cancer Res; 2007 Jul; 13(13):3883-91. PubMed ID: 17606721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response.
    Alexander BM; Chen MH; Carroll P; D'Amico AV
    Urology; 2007 Aug; 70(2):320-3. PubMed ID: 17826497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer.
    Ozenci V; Miller AM; Palmborg A; Egevad L; Jaremko GA; Kälkner KM; Pisa P
    Prostate; 2005 Sep; 65(1):20-6. PubMed ID: 15800933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
    Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.